Tag: PE

FDA clears AI-driven detection tool for pulmonary embolism

Medical imaging AI company Avicenna.AI has announced 510(k) clearance from the US Food and Drug Administration (FDA) for its CINA-iPE artificial intelligence (AI)-powered tool that...

Akura thrombectomy system for PE appears safe and demonstrates reduction of...

Results from a first-in-human, prospective, single-arm study of the Akura Medical thrombectomy system (Akura Medical) for pulmonary embolism (PE) were revealed this week at...

Aidoc’s AI solution for pulmonary embolism clinically proven to reduce hospital...

Research in the advancement of artificial intelligence (AI)-driven pulmonary embolism (PE) care was unveiled recently during the 9th Annual Pulmonary Embolism Symposium (Sept. 21–23)...

New clinical data support Viz.ai solution for improved pulmonary embolism detection...

Viz.ai has announced new clinical data supporting advancements in pulmonary embolism (PE) detection. Two studies have demonstrated the real-world clinical efficacy of Viz.ai's PE...

FLAME, FLASH and ongoing PEERLESS trials collect “compelling” data for FlowTriever...

Speaking on the FLAME, FLASH and PEERLESS trials that each collected data on the FlowTriever (Inari Medical) device for the treatment of pulmonary embolism...

Viz.ai to expedite patient enrolment in NIH-funded PE-TRACT clinical trial

Viz.ai has announced it will use its Viz Recruit platform to optimise patient enrolment for the National Institutes of Health (NIH)-funded Pulmonary embolism—thrombus removal...
filters

New study demonstrates IVC filters “safe and effective” in treating venous...

Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into...

New mechanical thrombectomy systems unlock possibilities for the treatment of venous...

 Gerd Grözinger (Tübingen, Germany) chats with Bernhard Gebauer (Berlin, Germany) at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14...
RapidAI

RapidAI receives FDA 510(k) clearance for PE Triage & Notification

RapidAI announced today that it has received US Food and Drug Administration (FDA) 510(k) clearance for its Rapid PE Triage & Notification product for...
Charles Ritchie and Young Erben

Anticoagulants effective for pulmonary embolism resolution in hospitalised COVID-19 patients

Anticoagulants alone are associated with a high rate of resolution of pulmonary embolism (PE) in patients with acute PE and COVID-19 infection. This was...

Viz.ai launches two new AI-powered modules for pulmonary embolism and aortic...

Viz.ai has announced the US commercial launch of its AI-powered modules for pulmonary embolism and aortic disease. Debuting at VEITHsymposium 2021 (16–20 November, Orlando, USA), the...
FlowTriever

Inari Medical announces six-month FLASH registry interim data

Inari Medical has announced positive acute and long-term interim results from the first 500 pulmonary embolism (PE) patients enrolled in the FlowTriever outcomes registry...

Thromboprophylaxis with anticoagulants “likely effective” at preventing VTE post-vascular surgery, larger...

“Among patients undergoing vascular surgery, thromboprophylaxis with anticoagulants showed a trend towards reduced incidence of VTE when compared to placebo,” Tarek Haykal (Duke...

Viz.ai and Avicenna.AI partner to launch AI-driven intelligent care coordination for...

Viz.ai has partnered with Avicenna.AI to enable intelligent care coordination and improve patient triage of patients suffering from pulmonary embolism (PE) and aortic disease. Avicenna.AI’s US...
Thrombolex bashir

Thrombolex receives enhanced indication for use from the FDA

The US Food and Drug Administration (FDA) has enhanced the indications for use of the Bashir endovascular catheter (Thrombolex) and the Bashir Plus endovascular...

Propofol use during catheter-directed interventions for intermediate-risk PE associated with major...

A study suggests avoiding propofol for intraprocedural sedation during catheter-directed interventions (CDIs) for intermediate-risk pulmonary embolism (PE) because it can have detrimental effects. Propofol...

AI triage solution for PE and aortic dissection receives FDA clearance...

Medical imaging artificial intelligence (AI) specialist Avicenna.AI recently announced that it has received certification in the USA and European Union (EU) for CINA CHEST,...

Aidoc and Imbio partner to provide an AI solution to prioritise...

Aidoc and Imbio have announced a partnership intended to provide an end-to-end artificial intelligence (AI) solution for pulmonary embolism (PE), with the goal of ultimately...

HOME-PE trial clarifies which patients with acute PE can be managed...

Patients with acute pulmonary embolism (PE) can be selected for home management using the sPESI score or the Hestia criteria, according to results of...

Study finds death rates from PE have been rising over the...

The American Heart Association (AHA) has announced that after nearly a decade of steady decline, the death rate for people with pulmonary embolism (PE)...
reduced hospital time and costs Xarelto anticoagulant

FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...

First European advice on deep vein thrombosis published in European Heart...

The first comprehensive European advice on deep vein thrombosis was recently published in the European Heart Journal. The recommendations were produced by the European...
Venous News for specialists

GARFIELD-VTE Registry sheds light on global heterogeneity of venous thromboembolism patients,...

The first results from the GARFIELD-VTE (Global anticoagulant registry in the field—venous thromboembolism) were presented at the International Society on Thrombosis and Haemostasis Congress...

FDA grants priority review of Xarelto for a 10mg dose to...

The US Food and Drug Administration (FDA) has accepted, for priority review, a supplemental new drug application (sNDA) for Janssen’s Xarelto (rivaroxaban), to include...